Stéphanie Bécourt

412 total citations
13 papers, 114 citations indexed

About

Stéphanie Bécourt is a scholar working on Oncology, Reproductive Medicine and Genetics. According to data from OpenAlex, Stéphanie Bécourt has authored 13 papers receiving a total of 114 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Oncology, 5 papers in Reproductive Medicine and 4 papers in Genetics. Recurrent topics in Stéphanie Bécourt's work include Ovarian cancer diagnosis and treatment (4 papers), BRCA gene mutations in cancer (3 papers) and Breast Cancer Treatment Studies (2 papers). Stéphanie Bécourt is often cited by papers focused on Ovarian cancer diagnosis and treatment (4 papers), BRCA gene mutations in cancer (3 papers) and Breast Cancer Treatment Studies (2 papers). Stéphanie Bécourt collaborates with scholars based in France, Italy and Denmark. Stéphanie Bécourt's co-authors include C. Hamonet, Justine Hugon‐Rodin, Anne Gompel, Delphine Hudry, Éric Leblanc, Carlos Martínez-Gómez, Samuel Meignan, Fabrice Narducci, Sylvain Ladoire and E. Bourstyn and has published in prestigious journals such as Journal of Clinical Oncology, Cancers and Frontiers in Oncology.

In The Last Decade

Stéphanie Bécourt

12 papers receiving 113 citations

Peers

Countries citing papers authored by Stéphanie Bécourt

Since Specialization

Citations

This map shows the geographic impact of Stéphanie Bécourt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stéphanie Bécourt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stéphanie Bécourt more than expected).

Fields of papers citing papers by Stéphanie Bécourt

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stéphanie Bécourt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stéphanie Bécourt. The network helps show where Stéphanie Bécourt may publish in the future.

Co-authorship network of co-authors of Stéphanie Bécourt

This figure shows the co-authorship network connecting the top 25 collaborators of Stéphanie Bécourt. A scholar is included among the top collaborators of Stéphanie Bécourt based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stéphanie Bécourt. Stéphanie Bécourt is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

13 of 13 papers shown

#	Work	Indexed citations
1	312P Efficacy of sequential antibody-drug conjugates (ADCs) targeting topoisomerase-1 in HER2-low metastatic breast cancer (MBC): Updated results and additional analyses from the French multicenter retrospective ADC-low cohort 2025 ·ESMO Open ·(unknown), (unknown), M. Reich, Martina Pagliuca, (unknown), Antoine Deleuze, Catherine Rivier, (unknown), (unknown), Sylvain Ladoire, (unknown), Christelle Lévy, Anne Patsouris, (unknown), Frédéric Fiteni, (unknown), (unknown), Stéphanie Bécourt, Alexandre de Nonneville, (unknown)	1
2	Breast Cancer Prognosis in Young BRCA1/BRCA2 Mutation Carriers: A Retrospective Hospital-based Cohort Study 2024 ·Clinical Oncology ·(unknown), (unknown), Stany Chrétien, Christophe Piérard, (unknown), Stéphanie Bécourt, L. Boulanger, L. Ceugnart, (unknown), (unknown), Audrey Mailliez	1
3	181P Male breast cancer (MBC): Familial history (FH), clinicopathological (CP) characteristics, oncogenetic (OG) testing and outcome in a cohort of 98 patients (pts) 2023 ·ESMO Open ·(unknown), (unknown), (unknown), M. Le Deley, (unknown), (unknown), Stéphanie Bécourt, Audrey Mailliez	1
4	#161 Final overall survival and long-term safety in the ENGOT-OV16/NOVA phase 3 trial of niraparib in patients with recurrent ovarian cancer 2023 ·Mansoor Raza Mirza, Jørn Herrstedt, Amit M. Oza, Sven Mahner, Andrés Redondo, Dominique Berton-Rigaud, Jonathan S. Berek, Charlotte Aaquist Haslund, Frederik Marmé, Antonio González-Martı́n, Stéphanie Bécourt, Anna V. Tinker, Jonathan A. Ledermann, Benedict B. Benigno, Gabriel Lindahl, Nicoletta Colombo, Izabela A. Malinowska, Wenlei Liu, Bradley J. Monk, Ursula A. Matulonis	8
5	16 Months Follow Up of Patients’ Behavior and Mild COVID-19 Patterns in a Large Cohort of Cancer Patients During the Pandemic 2022 ·Frontiers in Oncology ·Nawale Hajjaji, (unknown), (unknown), Stéphanie Bécourt, (unknown), (unknown), (unknown), (unknown), Éric Lartigau	7
6	Primary or Interval Debulking Surgery in Advanced Ovarian Cancer: a Personalized Decision—a Literature Review 2022 ·Current Oncology Reports ·Delphine Hudry, Stéphanie Bécourt, Giovanni Scambia, (unknown)	4
7	The promising prognostic value of vagal nerve activity at the initial management of ovarian cancer 2022 ·Frontiers in Oncology ·(unknown), Sophie Lefèvre‐Arbogast, (unknown), Cyril Abdeddaim, Stéphanie Bécourt, Nicolas Penel, Elodie Coquan, Justine Lequesne, Yori Gidron, Florence Joly	9
8	Prognostic impact of tumor size reduction assessed by magnetic resonance imaging after radiochemotherapy in patients with locally advanced cervical cancer 2022 ·Frontiers in Oncology ·(unknown), (unknown), Alexandre Escande, S. Taïeb, (unknown), Marie‐Cécile Le Deley, Andrée Michel, (unknown), Delphine Hudry, Carlos Augusto Real Martinez, Éric Leblanc, Stéphanie Bécourt, (unknown), (unknown), Éric Lartigau, X. Mirabel, Fabrice Narducci	4
9	Tumor-Infiltrating Lymphocytes (TILs) in Epithelial Ovarian Cancer: Heterogeneity, Prognostic Impact, and Relationship with Immune Checkpoints 2022 ·Cancers ·Delphine Hudry, (unknown), Samuel Meignan, Stéphanie Bécourt, (unknown), (unknown), Carlos Martínez-Gómez, Éric Leblanc, Fabrice Narducci, Sylvain Ladoire	19
10	Prognostic Impact of Stromal Immune Infiltration before and after Neoadjuvant Chemotherapy (NAC) in Triple Negative Inflammatory Breast Cancers (TNIBC) Treated with Dose-Dense Dose-Intense NAC 2020 ·Cancers ·Luca Campedel, Paul Blanc‐Durand, (unknown), Jacqueline Lehmann‐Che, C. Cuvier, C. de Bazelaire, Luís Teixeira, Stéphanie Bécourt, (unknown), (unknown), E. Bourstyn, Catherine Miquel, S. Guillerm, (unknown), Marc Espié, Anne de Roquancourt, Anne‐Sophie Hamy, Sylvie Giacchetti	6
11	Comparison of clinicopathological (CP) features and outcome of breast cancers (BC) in BRCA-mutation carriers patients, with a family history without BRCA-mutation and with sporadic disease. 2018 ·Journal of Clinical Oncology ·Stéphanie Bécourt, Odile Cohen‐Haguenauer, (unknown), (unknown), C. Cuvier, Sylvie Giacchetti, (unknown), E. Bourstyn, Marc Espié, Luís Teixeira	4
12	Cancer lobulaire infiltrant : épidémiologie, histoire naturelle, principes thérapeutiques 2017 ·Imagerie de la Femme ·Marc Espié, Stéphanie Bécourt, (unknown)	0
13	Gynecologic symptoms and the influence on reproductive life in 386 women with hypermobility type ehlers-danlos syndrome: a cohort study 2016 ·Orphanet Journal of Rare Diseases ·Justine Hugon‐Rodin, (unknown), Stéphanie Bécourt, C. Hamonet, Anne Gompel	50

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact